Drug profile · INN
letermovir
PREVYMIS
letermovir (PREVYMIS) is a dna terminase inhibitor. Route of administration: oral. Current US regulatory status: approved.
FDA: approved EMA: approved PMDA: approved Antiinfectives for systemic use (J05) J05
US status approved
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — letermovir
- US status
- approved
- Class
- Antiinfectives for systemic use (J05)
- Route
- ORAL
- Patents
- 0
- Programs
- 2
- Data quality
- 0.84
Quick answer
letermovir (PREVYMIS) is a dna terminase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
INN letermovir
Brand PREVYMIS
Mechanism DNA terminase inhibitor
Target DNA terminase
Therapeutic class Antiinfectives for systemic use (J05)
Route ORAL
Formulation SOLUTION
ATC code J05
Mechanism of action
DNA terminase inhibitor
Primary target: DNA terminase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is letermovir?
letermovir (PREVYMIS) is a dna terminase inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for letermovir?
PREVYMIS is a marketed brand name for letermovir. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of letermovir?
letermovir has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.